LGALS3 and acute lymphoblastic leukemia: MSCs can also protect ALL cells against the treatment by secretion of soluble or stroma-cell-bound galectin-3, which stimulates expression of endogenous LGALS3 mRNA and activates the tonic NF-κB pathway in leukemic cells [78].